GILEAD SCIENCES, INC.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
GILD$170.87+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| (in millions) | 2025 | 2024 |
| Operating Activities: | ||
| Net income (loss) | $6,327 | $(1,303) |
| Adjustments to reconcile Net income (loss) to Net cash provided by operating activities: | ||
| Depreciation expense | 280 | 286 |
| Amortization expense | 1,793 | 1,788 |
| Stock-based compensation expense | 664 | 613 |
| Deferred income taxes | 282 | (1,465) |
| Net (gain) loss from equity securities | (198) | 148 |
| Acquired in-process research and development expenses | 485 | 4,674 |
| In-process research and development impairments | 190 | 4,180 |
| Other, net | 213 | 294 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (546) | 67 |
| Inventories | (913) | (200) |
| Prepaid expenses and other | (275) | (113) |
| Accounts payable | (37) | 348 |
| Income tax assets and liabilities, net | (1,974) | (1,268) |
| Accrued and other liabilities | 401 | (197) |
| Net cash provided by operating activities | 6,692 | 7,853 |
| Investing Activities: | ||
| Purchases of marketable debt securities | (2,557) | (244) |
| Proceeds from sales of marketable debt securities | 514 | 2,265 |
| Proceeds from maturities of marketable debt securities | 32 | 327 |
| Acquisitions, including in-process research and development, net of cash acquired | (461) | (4,765) |
| Purchases of equity securities | (119) | (453) |
| Purchases of property, plant and equipment | (358) | (376) |
| Other investing activities, net | (9) | 23 |
| Net cash used in investing activities | (2,958) | (3,224) |
| Financing Activities: | ||
| Proceeds from issuances of common stock | 376 | 249 |
| Repurchases of common stock under repurchase programs | (1,692) | (800) |
| Repayments of debt and other obligations | (1,780) | (1,963) |
| Payments of dividends | (3,009) | (2,945) |
| Other financing activities, net | (377) | (234) |
| Net cash used in financing activities | (6,482) | (5,693) |
| Effect of exchange rate changes on cash and cash equivalents | 87 | 15 |
| Net change in cash and cash equivalents | (2,661) | (1,049) |
| Cash and cash equivalents at beginning of period | 9,991 | 6,085 |
| Cash and cash equivalents at end of period | $7,330 | $5,037 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.